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Aims The EUTrigTreat clinical study has been designed as a prospective multicentre observational study and aims to (i) risk
stratifypatientswithanimplantablecardioverterdeﬁbrillator(ICD)formortalityandshockriskusingmultiplenoveland
established risk markers, (ii) explore a link between repolarization biomarkers and genetics ofion (Ca
2+,N a
+,K
+) me-
tabolism, (iii) compare the results of invasive and non-invasive electrophysiological (EP) testing, (iv) assess changes of
non-invasive risk stratiﬁcation tests over time, and (v) associate arrythmogenomic risk through 19 candidate genes.
Methods
and results
Patients with clinical ICD indication are eligible for the trial. Upon inclusion, patients will undergo non-invasive risk
stratiﬁcation, including beat-to-beat variability of repolarization (BVR), T-wave alternans, T-wave morphology vari-
ables, ambient arrhythmias from Holter, heart rate variability, and heart rate turbulence. Non-invasive or invasive
programmed electrical stimulation will assess inducibility of ventricular arrhythmias, with the latter including record-
ings of monophasic action potentials and assessment of restitution properties. Established candidate genes are
screened for variants. The primary endpoint is all-cause mortality, while one of the secondary endpoints is ICD
shock risk. A mean follow-up of 3.3 years is anticipated. Non-invasive testing will be repeated annually during
follow-up. It has been calculated that 700 patients are required to identify risk predictors of the primary endpoint,
with a possible increase to 1000 patients based on interim risk analysis.
Conclusion The EUTrigTreat clinical study aims to overcome current shortcomings in sudden cardiac death risk stratiﬁcation and
to answer several related research questions. The initial patient recruitment is expected to be completed in July 2012,
and follow-up is expected to end in September 2014.
Clinicaltrials.gov identiﬁer: NCT01209494.
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Introduction
Sudden cardiac death (SCD) is one of the major challenges in
modern healthcare, accounting for an estimated 600 000 deaths
per year in Europe. In the majority of the cases, SCD is caused
by ventricular tachycardia (VT) or ventricular ﬁbrillation (VF).
1
Implantable cardioverter deﬁbrillator (ICD) treatment has been
established in both primary and secondary prevention of SCD.
2 Al-
though a variety of non-invasive risk stratiﬁcation techniques exist,
effective risk stratiﬁcation for the prevention of SCD in individual
patients remains a major clinical challenge:
3,4 The indication for
ICD therapy in primary prophylaxis of SCD is mainly based on
reduced left ventricular ejection fraction (LVEF), ,30–40%.
2 In
patients with reduced LVEF in the Sudden Cardiac Death in
Heart Failure Trial (SCD-HeFT), the incidence of appropriate
ICD therapy was found to be 31% over 5 years,
5 and appropriate
shocks were correlated with increased mortality.
6 Recently, certain
patient subgroups have been identiﬁed in whom death can occur
before a life-saving shock for a malignant tachyarrhythmia.
7 On
the other hand, the risk of inappropriate ICD shocks
8 is an import-
ant concern involving pain, anxiety, and reduced quality of life,
9 as
well as possible life-threatening risks.
10
As a consequence, at least some patients who receive an ICD in
line with current guidelines, will do so without future clinical
beneﬁt, but with the cost of the device and the risk of complica-
tions. The EUTrigTreat clinical study—a multicentre observational
risk stratiﬁcation study—investigates whether comprehensive as-
sessment of multiple electrophysiological (EP) risk stratiﬁcation
techniques that are independently associated with risk can
improve risk stratiﬁcation to improve patient selection for ICD
therapy. In addition, invasive and non-invasive programmed stimu-
lation have never been compared systematically, and hence, to
address this, a non-randomized comparison of these two modes
of EP study has been incorporated into the protocol.
Furthermore, we hypothesize that physiological or pathophysio-
logical links exist between repolarization variables and genetic
markers of cardiomyocyte ion metabolism. In particular, Ca
2+-,
Na
+-, and K
+-dependent EP mechanisms are investigated
through an array of prospectively screened candidate genes.
Finally, we aim to assess the dynamic time-dependent changes of
the non-invasive risk stratiﬁers that we use again during follow-up
as well as their prognostic implication.
Methods
Objectives and study design
The EUTrigTreat clinical ICD and arrhythmia risk investigation has
been designed as a prospective observational cohort study, including
comprehensive electrocardiogram (ECG)-based risk stratiﬁcation, can-
didate gene analyses, and either non-invasive or invasive EP study. The
study’s objectives are (i) to risk stratify a large cohort of ICD patients
for all-cause mortality and ICD shock risk and using a combination of:
T-wave morphology (TWM), signal-averaged ECG (SAECG), T-wave
alternans (TWA), beat-to-beat variability of repolarization (BVR),
24-hour Holter monitoring for ambient arrhythmia, heart rate variabil-
ity, and heart rate turbulence, as well as clinical characteristics including
standard laboratory markers; (ii) to characterize the relationships
between repolarization abnormalities identiﬁed by TWA, BVR,
TWM, restitution of repolarization, and genetic candidate mechanisms
of cardiac ion channel metabolism; (iii) to compare the results of inva-
sive and non-invasive EP testing in the two subgroups of the study; (iv)
to evaluate the dynamicity of time-dependent changes of BVR, TWM,
TWA, LVEF, and Holter, and a possible change in their prognostic
value over time; and (v) to evaluate 19 candidate genes with estab-
lished or suspected EP phenotype linkage as risk mediators in ICD
patients.
A total of 700 ICD patients will be recruited in ﬁve academic clinical
centres in Europe until mid-2012. On recruitment of 700 patients, a
sample size review will be carried out to determine whether additional
recruitment of up to 1000 ICD patients is necessary. Subjects sched-
uled for de novo ICD implantation or generator replacement are eli-
gible for invasive EP testing, whereas patients from the outpatient
ICD clinic undergo non-invasive EP testing. Indications for ICD im-
plantation are independent of study participation and follow current
guidelines.
2 Tables 1 and 2 summarize the patient inclusion and exclu-
sion criteria. Patients with coronary artery disease, including those with
a history of ST elevation myocardial infarction may be enrolled up to a
limit of 60% of the total number of patients. Patients with atrial ﬁbril-
lation as the underlying rhythm may be enrolled up to a limit of 20% of
the total number of patients.
Endpoints
Primary endpoint
The primary study endpoint is all-cause mortality during follow-up until
September 2014. The expected mean follow-up time is 3.3 years based
on the enrolment of 700 patients, and 2.8 years for the enrolment of
1000 patients according to the pre-speciﬁed interim statistical analysis.
Secondary endpoints
Secondary endpoints of the study are:
Sudden cardiac death, cardiac death, and non-cardiac death: The cause of
death will be adjudicated by a blinded endpoint committee and each
death will be classiﬁed as one of the following: SCD, cardiac death,
and non-cardiac death. Sudden cardiac death is deﬁned as death due
to any cardiac disease and occurrence within 1 h after the onset of
symptoms. A cardiac death is deﬁned as any death presumed to
have occurred from a cardiac cause other than SCD. Non-cardiac
deaths are all other deaths.
Appropriate and inappropriate ICD shocks: Implantable cardioverter de-
ﬁbrillator therapies will be adjudicated by the blinded endpoint
committee and classiﬁed as appropriate or inappropriate. An ICD
shock is classiﬁed as appropriate if delivered for a ventricular
tachyarrhythmia in the VT or VF detection zone. Based on the
episode data stored by the device, an appropriate ICD shock is clas-
siﬁed as (i) primarily delivered in the VF zone, (ii) delivered as a
backup to failed antitachycardia pacing (ATP) in the VT zone, or
(iii) delivered after acceleration of a failed ATP into the VF zone.
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of the study.
Each inappropriate shock will be classiﬁed as caused either by oversen-
sing of cardiac or non-cardiac electrical signals such as VT or VF, or by
inappropriate classiﬁcation of supraventricular tachycardia as VT by the
device, as veriﬁed by interpretation of the stored electrograms.
Secondary endpoint combining all-cause mortality and appropriate ICD
shocks: The combination of all-cause mortality and appropriate
ICD shocks is deﬁned as a composite secondary endpoint. The
combination of appropriate and inappropriate ICD shocks, i.e. any
ICD shocks, is deﬁned as another secondary composite endpoint.
Implantable cardioverter deﬁbrillator
programming
The investigators have discussed a mandatory ICD programming;
however, due to enrolment of patients in ﬁve different countries and
with a wide variety of ICD indications, this has not been deemed pos-
sible. It is therefore mandatory to document all ICD settings including
subsequent changes for the endpoints committee. In principle, it has
been agreed to adhere to current programming guidelines as set
forth by Spragg and Berger
11 as long as judged clinically useful for a re-
spective patient.
Study protocol
The study will be conducted in accordance with the Declaration of
Helsinki, the principles of the International Conference on Harmoniza-
tion of Good Clinical Practice,
12 and with the approval of all local
ethics committees. An outline of the study protocol is shown in
Figure 1. After written informed consent, non-invasive ECG-based
risk stratiﬁcation, EP study, and laboratory samples will be completed.
Echocardiography will be performed to measure LVEF. Cardiovascular
functional capacity will be assessed using the New York Heart Associ-
ation symptomatic class. Pulse rate, resting blood pressure, weight, and
height will be measured. Cardiovascular drug treatment will be docu-
mented along with the presence or absence of the following co-
morbidities: Obesity, renal disease, liver disease, anaemia, peripheral
arterial disease, cerebral vascular disease, pulmonary disease, metabol-
ic disease, hypertension, sleep apnea, tobacco use, hyperlipidaemia,
and family history of inherited cardiac disease or sudden death. Stand-
ard laboratory parameters will be analysed, including creatinine,
gamma-GT, high-sensitivity C-reactive protein, and N-terminal pro-
brain natriuretic protein.
Non-invasive electrocardiographic risk
stratiﬁcation
Twelve-lead electrocardiogram for T-wave morphology
The 12-lead surface ECG will be recorded using a standard digital
recording device. QRS duration, QT interval, QTc by the Bazett
formula, and standard TWM will be measured. The latter will be auto-
matically analysed as previously described,
13 and principal component
analysis ratio, total cosine R-to-T, TWM dispersion, normalized
T-wave loop area, T-wave loop dispersion, and relative T-wave re-
siduum will be computed.
Signal-averaged electrocardiogram for late potentials
Signal-averaged ECG will be recorded according to standard guidelines
and using standard equipment. Positivity for late potentials will be
determined, where at least two-third of positive criteria are present
in accordance with standardized grading rules.
14
T-wave alternans testing
Microvolt TWA testing will be performed using the Cambridge Heart
system and heart rate elevation by means of exercise.
15 Exercise inten-
sity is tailored to reach a target heart rate of 110–120 beats per
minute (bpm). The TWA test will be analysed by the proprietary soft-
ware immediately after the test. Test results will be graded in consen-
sus of two blinded investigators with expertise in interpreting
microvolt TWA results, according to the rules developed by Bloom-
ﬁeld et al.
15 The maximal TWA amplitude in the vector magnitude
and ECG leads will also be recorded.
Holter electrocardiogram
A 24-h Holter monitoring will be performed using a standard clinical
recording device. Data will be analysed for the number of premature
ventricular complexes and the number of episodes and rate of non-
sustained VT, normalized for a recording time of 24 h. Heart rate vari-
ability, including standard deviation of RR intervals (SDNN), root mean
square of successive differences in RR intervals (RMSSD), and fre-
quency domain parameters (low frequency/high frequency) will also
be calculated.
16 Heart rate turbulence comprising turbulence onset
and slope as well as acceleration and deceleration capacity will be
computed.
17
Table 2 Exclusion criteria
For invasive and non-invasive EP groups
Unstable cardiac disease, such as decompensated heart failure
(NYHA Class IV) or acute coronary syndrome or symptomatic
arrhythmias
Percutaneous coronary intervention orcoronaryartery bypass graft
surgery ≤3 months ago
RV pacing .20% of the time in single- and dual-chamber device
patients presenting for generator exchange
For non-invasive EP group
ICDs unable to deliver programmed ventricular stimulation via
programmer
Cardiac resynchronization therapy devices ,6 months after
implantation
EP, electrophysiological; ICD, implantable cardioverter deﬁbrillator; NYHA,
New York Heart Association; RV, right ventricular; SCD, sudden cardiac death.
Table 1 Inclusion criteria
Clinical indication (primary and secondary prevention of SCD) for
ICD implantation, ICD generator exchange; or chronically
implanted ICD
Age ≥ 18 years
Written informed consent
Negative pregnancy test in women of childbearing potential
No participation in other clinical trials within 1 month before and after
enrolment into the study
ICD, implantable cardioverter deﬁbrillator; SCD, sudden cardiac death.
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for SAECG, will be repeated at 6- and 12-month follow-up, and then
annually until the end of the study in September 2014.
Electrophysiological study
Invasive electrophysiological study
In patients scheduled for new ICD implantations or undergoing ICD
generator replacement, an invasive EP study will be performed.
Standard diagnostic EP catheters will be placed in the high right
atrium and in the His bundle position. A standard steerable Ag–
AgCl quadripolar catheter will be positioned in the right ventricular
(RV) apex and outﬂow tract to record and pace the monophasic
action potential (MAP).
18 Inducibility of ventricular arrhythmias will
be tested using an abbreviated Ann Arbor protocol
19 with four
extrastimuli from two RV locations (RV apex and RV outﬂow
tract). For comparability with the patient cohort undergoing non-
invasive EP testing, the protocol will also be conducted with three
extrastimuli. The 12-lead ECG and MAPs will be recorded at
various cycle lengths (1000, 857, 750, 667, 600, 545, 500, and
430 ms) during steady-state atrial and RV pacing for BVR analysis
20
as well as during atrially paced stepwise TWA.
21 Right ventricular
pacing with a single extrastimulus, starting at 600 ms basic cycle
length and decreasing towards refractoriness, will be performed for
calculation and graphical depiction of the electrical restitution
curve.
22 Furthermore, MAP signals will be analysed for action poten-
tial duration at 90% repolarization.
23
Non-invasive electrophysiological study
In patients with a chronically implanted ICD device (.3 months), an
EP study will be performed non-invasively using the ICD programmer.
Screening in ICD clinic and
new implantions
Enrolment
500 chronic ICD patients 200 new ICD patients
Non-invasive risk markers
TWM, TWA, SAECG
Genetic profile (Ca2+)
Environmental factors, concomitant disease
Clinical characteristics (LVEF)
Non-invasive EP test Invasive EP test
Inducibility Inducibility
TWA + BVR TWA + BVR
APD restitution
Vagal tone
HRV + HRT
Annually repeat non-invasive risk markers
Assessment of outcome/3–5 year follow-up
ICD shocks
mortality
Non-cardiac
mortality
Cardiac mortality
Sudden death
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Figure 1 Study work ﬂow. APD, action potential duration; BVR, beat-to-beat variability of repolarization [non-invasive part: 12-lead ECG
(electrocardiogram), invasive part: 12-lead ECG and MAP (monophasic action potential)]; EP, electrophysiological; HRT, heart-rate turbulence;
HRV, heart-rate variability; LVEF, left ventricular ejection fraction; ICD, implantable cardioverter deﬁbrillator; SAECG, signal-averaged ECG;
TWA, T-wave alternans; TWM, T-wave morphology.
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recordings will not be performed. Similar to the invasive EP study,
inducibility of ventricular arrhythmias will be tested following an abbre-
viated Ann Arbor protocol with three extrastimuli from the RV elec-
trode, as most of the ICD programmers cannot deliver four
extrastimuli. Comparability with inducibility in invasively studied
patients will be ensured by conducting invasive EP studies with both
three and four extrastimuli. The 12-lead ECG for BVR and TWA ana-
lysis will be recorded at the above-mentioned cycle lengths during
atrial and ventricular pacing wherever applicable, depending on the
patient’s ICD model and underlying rhythm. In patients receiving
cardiac resynchronization therapy with underlying atrioventricular
block, biventricular-paced TWA will be performed.
21 Beat-to-beat
variability of repolarization will be repeated after 6 months and then
once a year.
Candidate gene analysis
One rationale of the EUTrigTreat consortium is to characterize genetic
arrhythmia modiﬁers in patients with different cardiomyopathies and
to further differentiate arrhythmic substrates through a combined
translational experimental approach. In this regard, the scientiﬁc
focus is based on cardiac myocyte calcium and sodium metabolism
while other candidate genes were included to allow for more compre-
hensive patient genotyping, for instance, also involving potassium
channel variants as well as inherited cardiomyopathies.
Based on existing linkage and genome-wide association study
(GWAS) data, we have identiﬁed 19 candidate genes of interest
(Table 3). Inherited genetic variants in these 19 genes may increase
the risk of ventricular arrhythmias and SCD in some patients. The can-
didate genes include different cation channels and their subunits, genes
involved in intracellular calcium storage and homeostasis, sarcomeric,
and cytoskeletal genes.
24–28 Beta-1-receptor polymorphisms were
included because earlier studies have shown an as-yet controversial
functional role of these polymorphisms in heart failure. Allelic variants
of the HRC gene have been associated with an increased risk for ma-
lignant ventricular arrhythmias in 123 patients with idiopathic dilated
cardiomyopathy.
26 The 19 candidate genes are characterized through
select single-nucleotide polymorphism analysis and additional deep
gene sequencing. Analyses of promoter sequences and exon–intron
boundaries complement the genomic risk analysis. Based on recent
data from whole genome massively parallel exome resequencing,
29
we expect to identify  500 variants that may be associated with indi-
vidual arrhythmogenic risk. The genetic data will be correlated both
with non-invasive and invasive surrogate arrhythmogenic markers
and physiological parameters. An important aim are association
studies that address an objective of gene–environment interactions
phenotypically manifested as traits of cardiac EP behaviour, for
example TWA or electrical restitution. In addition, correlation of
genomic variation with clinical outcomes is also of interest, but
limited by overall sample size and therefore not available as GWAS
strategy. However, in a secondary analysis, we will attempt to identify
genes associated with the outcome variables. With an anticipated 500
variants, the predeﬁned conservative estimate of the level of signiﬁ-
cance for genetic variables is 0.0001. In addition to the primary analysis,
metabolic phenotypes including diabetes and obesity will be analysed
in relation to the anticipated 500 genetic variants with minor allele fre-
quencies of .3%. Furthermore, the genetic variants will be classiﬁed
into six groups according to their genomic localization and likelihood
of functionality, and these data will be associated with the primary
and secondary outcomes. Our primary hypothesis in the analysis of
all the genomic variants is the existence of a co-dominant mode of in-
heritance, i.e. the phenotype of heterozygous carriers is expected to
lie between the phenotype of homozygous wild type and homozygous
variant genotype for a given arrhythmia risk trait.
Committees
Clinical study steering panel
This panel will discuss the progress and timeline of the clinical study,
and will supervise the study management. In cooperation with the cen-
tralized clinical research organization monitoring, this committee
enforces adherence to good clinical practice and ethical standards.
Clinical as well as biostatistical expertise will be provided on this
panel. Because of the non-interventional nature of the present
cohort study, no independent data safety monitoring board has been
established for the study.
Endpoint committee
This committee is responsible for adjudicating mode of death and ICD
shocks. For this purpose, database information, clinical narratives as
well as original ICD episode printouts are made available for the com-
mittee meetings.
Statistics
Sample-size calculation
Three pivotal ICD studies involving ICD populations treated for
primary and secondary prophylaxis
5,30,31 were considered in the
sample-size calculation. In the AVID trial
30 of secondary ICD prophy-
laxis, a 2-year mortality of 18.4% and a 3-year mortality of 24.6%, re-
spectively, were observed in the ICD group. A history of myocardial
infarction was prevalent in 67% of 1016 patients. The DEFINITE
study
31 enrolled 458 patients with non-ischaemic dilated cardiomyop-
athy, and a total of 229 patients were randomized to primary preven-
tion ICD therapy. Their all-cause mortality over 4 years was 21%.
Third, the SCD-HeFT trial
5 for primary ICD prophylaxis of SCD was
conducted in 2521 patients with symptomatic heart failure and LV dys-
function. Of these, 52% exhibited ischaemic cardiomyopathy, while the
remaining 48% had non-ischaemic cardiomyopathy. Among three
treatment arms, 820 patients were randomized to ICD treatment.
Their all-cause mortality was 28.9% after 5 years, with 35.9% for the
ischaemic cardiomyopathy subgroup and 21.4% for the non-ischaemic
cardiomyopathy subgroup. The MADIT-II trial
32 exclusively enrolled
patients with ischaemic cardiomyopathy and was therefore not consid-
ered for sample-size calculations. Integrating the information from the
three trials, all-cause mortality is observed to be higher in patients re-
ceiving ICD therapy for secondary prophylaxis of SCD, while patients
Table 3 Candidate genes involved in diseases at risk of
sudden cardiac death
Channelopathies of sodium
channels
SCN5A SCN1B
Channelopathies of potassium
channels
KCNQ1 KCNH2
Cellular calcium metabolism NCX1 HSP20
ANK2 CASQ2
PLN HAX1
HRC RyR2
ASPH
Cardiac cytoskeleton DMD, ANK2
Hypertrophic cardiomyopathy Troponin (TNNT2,TNNI3,TNNC1)
Adrenergic beta-1 receptor ADRB1
J. Seegers et al. 420with ischaemic cardiomyopathy exhibit a higher mortality than those
with non-ischaemic cardiomyopathy. Annual mortality ranges
between 4.3% for non-ischaemic cardiomyopathy/primary prophylaxis
in SCD-HeFT, 5.3% for non-ischaemic cardiomyopathy/primary
prophylaxis in DEFINITE, 7.2% for ischaemic cardiomyopathy/
primary prophylaxis in SCD-HeFT, and 9.2% for ischaemic and non-
ischaemic cardiomyopathy/secondary prophylaxis in AVID. In the
EUTrigTreat clinical study, enrolment of a high proportion of patients
with secondary prevention ICDs is expected. Furthermore, up to 60%
of the patients with ischaemic cardiomyopathy and reduced LVEF are
enrolled. We therefore anticipate a mortality of ≈7% per year, or 28%
over a 4-year mean follow-up, for the purpose of sample-size calcula-
tion. A sample size of 632 patients then provides 80% power at a two-
sided signiﬁcance level of 5%, assuming 4-year mortalities of 23 and
33% in equally sized low- and high-risk groups, respectively, deﬁned
by a binary risk predictor (constituting a risk ratio of 1.65). Such pre-
dictors may be an ECG test, EP study result, or a genetic pattern, and
might result from dichotomizing a continuous variable. Allowing for
10% withdrawals, we aim to recruit a total of 700 patients. Owing
to improved pharmacological treatment and optimized revasculariza-
tion since the conduct of the three pivotal ICD studies, the respective
risk numbers derived may need to be adjusted towards signiﬁcantly
lower risk for the enrolment and observation period involved for
the current study. Although these sample-size calculations are based
on the best mortality estimates available from the literature, some un-
certainty remains with regard to a potentially lower long-term mortal-
ity rate in the particular population enrolled. Therefore, the sample
size will be recalculated after inclusion of the ﬁrst 700 patients in
June 2012, and might be raised up to a maximum total sample size
of 1000 patients in the event of lower-than-expected event
rates.
33,34 Enrolment will be stopped 6 months before the end of
the study at the latest, providing a follow-up of ≥6 months in every
patient. This sample size is expected to be sufﬁcient for analyses in-
volving secondary endpoints, ICD shocks, and appropriate shocks,
for which 4-year probabilities of 64 and 50%, respectively, are
assumed. Risk differences between equally sized risk groups of 11 per-
centage points for ICD shocks and 12 percentage points for appropri-
ate shocks will lead to power values in excess of 80%. Importantly, the
study is not powered for correlation of its genetic results with
outcome. Therefore, correlations of genetic results with phenotype
or phenotypic ﬁndings of the diagnostic methods are prioritized. A
control group of patients without an ICD was not considered due
to the overall very low risk of such patients and the fact that
low-risk patient subgroups are expected from within the ‘diverse-risk’
ICD cohort.
Statistical analysis plan
In univariate analyses, the effects of dichotomized continuous variables
and categorical variables will be described by Kaplan–Meier curves
compared by log-rank tests. Correction for multiplicity of testing is
planned by identiﬁcation of correlations between the variables, i.e.
those of autonomic tone. Cox regression analyses will be performed
to quantify the predictive value of combinations of categorical variables
and dichotomized continuous variables on the primary and secondary
time-to-event endpoints (e.g. mortality or shocks). The independent
predictive value of any variable will be determined. Useful combina-
tions of independently predictive variables will be explored to establish
risk scores for the prediction of mortality, ICD shocks, or any of the
predeﬁned primary or secondary endpoints. The signiﬁcance of pre-
dictive genetic markers from high-dimensional data will be assessed
in Cox regression models using appropriate approaches, such as
boosting or permutation tests with potential confounders being
included as covariates. Classiﬁcation models will be validated using
cross-validation.
Time line
The ﬁrst patient was enrolled in January 2010; currently, 340 patients
have been included. Recruitment of 700 patients is expected to be
complete in July 2012, with a possible extension to 1000 patients
scheduled until June 2014. The study ends in September 2014.
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